1080-79-1

Usage

Uses

Used in Pharmaceutical Synthesis:
Diethyl 1H-imidazole-4,5-dicarboxylate is used as a precursor in the synthesis of various pharmaceuticals and organic compounds. Its reactivity and functional groups make it a versatile building block for creating new molecules with potential therapeutic properties.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, Diethyl 1H-imidazole-4,5-dicarboxylate is utilized as a key intermediate for the development of novel drug candidates. Its unique structure and properties can be exploited to design and synthesize new compounds with improved pharmacological profiles, such as enhanced potency, selectivity, and bioavailability.
Used in Drug Discovery:
Diethyl 1H-imidazole-4,5-dicarboxylate plays a crucial role in drug discovery, where it serves as a starting material for the synthesis of potential drug candidates. Its presence in various chemical libraries allows researchers to explore its reactivity and evaluate its potential as a therapeutic agent in different disease areas.
Used in Chemical Research:
Diethyl 1H-imidazole-4,5-dicarboxylate is also employed in chemical research to study the reactivity and properties of imidazole-based compounds. This knowledge can be applied to develop new synthetic methods, improve existing processes, and discover new applications for this versatile chemical compound.

InChI:InChI=1/C12H10BrNO/c13-11-6-12(8-14-7-11)15-9-10-4-2-1-3-5-10/h1-8H,9H2

Upstream product

• 570-22-9 4,5-imidazoledicarboxylic acid 
• 64-17-5 ethanol 
• 59743-08-7 diethyl 2,3-dioxosuccinate 
• 100-97-0 hexamethylenetetramine 
• 69039-88-9 diethyl 2-mercapto-4,5-imidazoledicarboxylate 
• 78595-41-2 1,6-diethoxycarbonyldiimidazo<1,5-a; 1',5'-d>pyrazine-5,10-dione 
• 50-00-0 formaldehyd 
• 87-91-2 diethyl (2R,3R)-tartrate 

Downstream Products

• 33457-48-6 4,5-dihydroxymethylimidazole 
• 5423-20-1 1H-imidazole-4,5-dicarboxylic acid dihydrazide 
• 1232-51-5 diethyl ester of 1-benzylimidazole-4,5-dicarboxylic acid 
• 1210-92-0 diethyl 1-methylimidazol-1H-yl-4,5-dicarboxylate 
• 773099-17-5 2-bromo-1H-imidazole-4,5-dicarboxylic acid 
• 148320-44-9 1-benzyl-4,5-di-(chloromethyl)imidazole 
• 33457-07-7 1-benzyl-4,5-di-(hydroxymethyl)imidazole 
• 131727-38-3 N-(phenyl)-N-[1-(2-(4,5-diethoxycarbonyl-1H-imidazol-1-yl)-ethyl)-4-methoxycarbonyl-4-piperidinyl]-propanamide 
• 6293-09-0 5,6-dihydro-1H-imidazo[4,5-d]pyridazine-4,7-dione 
• 68120-00-3 1-(3,4-dichloro-benzyl)-1H-imidazole-4,5-dicarboxylic acid diethyl ester 
• 202278-29-3 1,7-dimethyl-1,5-dihydro-4H-imidazo[4,5-d]pyridazin-4-one 
• 5422-71-9 4,7-dichloro-1-methyl-1H-imidazo[4,5-d]pyridazine 

Relevant academic research and scientific papers

A new synthesis of carmethizole and related nitrogen analogues

A new efficient six-step synthesis of carmethizole, a novel big- carbamate alkylating agent, and syntheses of related nitrogen analogues are described, using a key 4,5-disubstituted imidazole intermediate 8.

Intramolecular hydrogen bond strength and pKa determination of N,N′-disubstituted imidazole-4,5-dicarboxamides

(Chemical Equation Presented) N,N′-Disubstituted imidazole-4,5- dicarboxamides (I45DCs) form an intramolecular hydrogen bond worth an estimated 14 ± 1 kcal/mol, as measured with a model structure in DMSO-d6 at 3 mM, thereby predisposing the molecular conformation to a folded rather than extended form. The I45DCs also show evidence of aggregation in both CDCl3 (>1 mM) and DMSO-d6 (>10 mM) solutions. These compounds are uncharacteristically weak bases in comparison with imidazoles bearing similar electron-withdrawing groups.

Synthesis of [1,3, NH2-15N3] (5′S)-8,5′-cyclo-2′-deoxyguanosine

To facilitate NMR studies and low-level detection in biological samples by mass spectrometry, [1,3, NH2-15N3] (5′S)-8,5′-cyclo-2′-deoxyguanosine was synthesized from imidazole-4,5-dicarboxylic acid in 21 steps. The three

METHOD FOR PRODUCING 1-BIPHENYLMETHYLIMIDAZOLE COMPOUND

The present invention provides a method for producing a 1-biphenylmethylimidazole compound having superior angiotensin II receptor antagonistic activity, or an intermediate thereof. The present invention provides a method for producing a compound having the formula (5) (R1 , Ra : H, an alkyl group) by oxidizing a compound having the formula (1) (R a : H, an alkyl group) using an oxidizing agent in the presence of a radical initiation reagent, and then reacting with an ammonia-generating reagent and a compound having the formula R 1 CHO (R 1 : H, an alkyl group) or a compound having the formula R1C(ORb)3 (R1: H,an alkyl group; Rb : an alkyl group).

Monocyclic L-nucleosides, analogs and uses thereof

Novel monocyclic L- nucleoside compounds have general formula (I). Embodiments of these compounds are contemplated to be useful in treating a wide variety of diseases including infections, infestations, neoplasms, and autoimmune diseases. Viewed in terms of mechanism, embodiments of the novel compounds show immunomodulatory activity, and are expected to be useful in modulating the cytokine pattern, including modulation of Th 1 and Th 2 response.

Monocyclic L-Nucleosides, analogs and uses thereof

Novel monocyclic L-Nucleoside compounds have the general formula STR1 Embodiments of these compounds are contemplated to be useful in treating a wide variety of diseases including infections, infestations, neoplasms, and autoimmune diseases. Viewed in terms of mechanism, embodiments of the novel compounds show immunomodulatory activity, and are expected to be useful in modulating the cytokine pattern, including modulation of Th1 and Th2 response.

Design, synthesis and evaluation of imidazolylmethyl carbamate prodrugs of alkylating agents

Two approaches to prodrugs of alkylating agents based on an imidazolylmethyl carbamate nucleus were explored. A 2-azido analogue (3) of the bis-carbamate carmethizole (1) displayed similar aerobic cytotoxicity to 1 in a panel of human and murine cell lines. Approaches to the 2-amino and 2- carbamoyl analogues are described. In the second approach an imidazolylmethanol was used as a 'trigger' linked via a carbamate to the alkylating agent N,N-bis(2-chlorethyl)amine (BCEA). Nitroimidazole and methylsulphinylimidazole carbamate prodrugs 6-8 were 5-20-fold less toxic than BCEA. Despite this deactivation in the prodrug form, little increase in cytotoxicity was observed under hypoxia. The data suggest that BCEA released on bioreduction is not sufficiently potent to contribute significant additional cytotoxicity. (C) 2000 Elsevier Science Ltd.

15N-Multilabeled Adenine and Guanine Nucleosides. Syntheses of [1,3,NH2-15N3]- and [2-13C-1,3,NH2-15N3]-Labeled Adenosine, Guanosine, 2′-Deoxyadenosine, and 2′-Deoxyguanosine

We report a high-yield route to the following specifically 15N- and 13C-multilabeled nucleosides: [1,3,NH2-15N3]- and [2-13C-1,3,NH2-15N3]-adenosine; [1,3,NH2-15N3]- and [2-13C-1,3,NH2-15N3]-guanosine; [1,3,NH2-15N3]- and [2-13C-1,3,NH2-15N 3]-2′-deoxyadenosine; [1,3,NH2-15N3]- and [2-13C-1,3,-NH2-15N 3]-2′-deoxyguanosine. In each set, the 13C2 atom functions as a "tag" that allows the 15N1 and 15N3 atoms to be unambiguously differentiated from the untagged versions in 15N NMR of RNA or DNA fragments. The key intermediate of this synthetic strategy for both the adenine and guanine nucleosides is [NH2,CONH2-15N 2]-5-amino-4-iimdazolecarboxamide. The [2-13C]-label is added through a ring closure using [13C]-sodium ethyl xanthate (NaS13CSOEt). Enzymatic transglycosylation of either multilabeled 6-chloropurine or multilabeled 2-mercaptohypoxanthine and a final reaction with 15NH3 give the adenine and guanine nucleosides. This is the first report of a [3-15N]-labeled guanine nucleoside.

2-substituted indane-2-mercaptoacetylamide tricyclic derivatives useful as inhibitors of enkephalinase

The present invention relates to novel 2-substitited indane-2-mercaptoacetylamide tricyclic derivatives which are useful as inhibitors of Enkephalise.